As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Patients with lung adenocarcinoma typically carry a mutation in the Epidermal Growth Factor Receptor (EGFR) gene, making them ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...